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Lymphoid and nonlymphoid classical DCs 
(cDCs) develop from pre-DCs, which are 
committed precursors that arise in the bone mar-
row and travel through the blood to seed lym-
phoid and nonlymphoid organs (Liu et al., 2007, 
2009; Waskow et al., 2008; Bogunovic et al., 
2009; Ginhoux et al., 2009). After arriving in 
peripheral tissues, pre-DCs differentiate into a 
diverse group of antigen-presenting cells under 
the influence of the cytokine Flt3L, an essential 
growth factor for all cDCs (Karsunky et al., 
2003; Naik et al., 2005; Waskow et al., 2008).
There are two major subsets of pre-DC–
derived cDCs in lymphoid and nonlymphoid 
organs. cDCs in lymphoid organs can be dis-
tinguished by differential expression of CD4 
and CD8, and in nonlymphoid tissues by ex-
pression of CD11b and CD103 (Helft et al., 
2010; Liu and Nussenzweig 2010). Nonlym-
phoid tissue CD103+ cDCs correspond to 
lymphoid CD8+ cDCs, whereas nonlymphoid 
tissue CD11b+ DCs are more heterogenous 
(Hashimoto et al., 2011). Although both subsets 
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Classical dendritic cells (cDCs) process and present antigens to T cells. Under steady-state 
conditions, antigen presentation by cDCs induces tolerance. In contrast, during infection or 
inflammation, cDCs become activated, express higher levels of cell surface MHC molecules, 
and induce strong adaptive immune responses. We recently identified a cDC-restricted zinc 
finger transcription factor, zDC (also known as Zbtb46 or Btbd4), that is not expressed by 
other immune cell populations, including plasmacytoid DCs, monocytes, or macrophages. We 
define the zDC consensus DNA binding motif and the genes regulated by zDC using chromatin 
immunoprecipitation and deep sequencing. By deleting zDC from the mouse genome, we show 
that zDC is primarily a negative regulator of cDC gene expression. zDC deficiency alters the 
cDC subset composition in the spleen in favor of CD8+ DCs, up-regulates activation pathways 
in steady-state cDCs, including elevated MHC II expression, and enhances cDC production of 
vascular endothelial growth factor leading to increased vascularization of skin-draining lymph 
nodes. Consistent with these observations, zDC protein expression is rapidly down-regulated 
after TLR stimulation. Thus, zDC is a TLR-responsive, cDC-specific transcriptional repressor 
that is in part responsible for preventing cDC maturation in the steady state.
© 2012 Meredith et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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zDC-targeted genes represent a highly diverse group of 
genes, the largest number of which is implicated in regulation 
of gene expression, including transcription factors, RNA 
processing factors, and chromatin regulators (Fig. 1 E and 
Table S1). A second large group of zDC-associated genes 
regulate protein metabolism, including kinases, peptidases, 
ubiquitin ligases, and phosphatases. Although zDC target 
genes are spread throughout the genome, they are most 
abundant on chromosome 17 in the region of the mouse 
MHC locus (Fig. 1 F). In fact, zDC is associated with all 
the MHC II genes expressed in C57BL/6 mice (Fig. 1 B). We 
conclude that zDC binds a variety of genes in cDCs, including 
MHC II antigens.
Members of the BTB-ZF family are typically transcrip-
tional repressors but have also been shown to function as 
transcriptional activators (Collins et al., 2001; Kelly and 
Daniel 2006; Beaulieu and Sant’Angelo 2011). To begin to 
define the role of zDC in regulating gene expression in vivo, 
we compared the expression of zDC target gene mRNAs 
in fully differentiated cDCs and monocytes by gene array. 
Monocytes were selected for comparison because they are 
closely related to cDCs but lack zDC expression (Meredith 
et al., 2012; Satpathy et al., 2012). Consistent with the ability 
of BTB-ZF transcription factors to function as suppressors 
or activators, we found a broad range of differential gene expres-
sion of zDC target genes in cDC and monocytes (Fig. 1 G). 
564 zDC-associated gene probes were expressed at two- to 
fourfold higher levels in monocytes compared with cDCs 
(57% of ChIP target gene probes differentially expressed 
between cDCs and monocytes; Fig. 1 G). This pattern suggests 
that zDC suppresses the expression of these genes in dif-
ferentiated cDCs. Conversely, a smaller group of genes 
(381 probes; 40% of differentially expressed ChIP gene probes) 
was up-regulated in cDCs compared with monocytes, repre-
senting targets that may be activated by zDC binding. There-
fore, like other BTB-ZF family members, zDC represses the 
expression of many of its target genes but can also activate 
gene expression.
zDC is not required for cDC development
To examine the function of zDC in vivo, we produced a 
conditional knockout of zDC by flanking its second exon, 
which encodes the translational start site and the BTB 
protein-binding domain, with loxP sites (Fig. 2 A, zDClox/lox 
mice). These mice were generated and maintained on the 
C57BL/6 background. zDClox/lox mice were crossed with 
EIIA-Cre mice to produce mice that carry a zDC null 
mutation (zDC/).
Despite the absence of zDC protein in mutant mice (Fig. 2 B), 
early cDC development was unaffected. We found normal 
numbers of macrophage and DC progenitors, common DC 
progenitors, and pre-cDCs in the bone marrow (Fig. 2 C). 
Furthermore, the total number of cDCs in the spleen and 
skin-draining LNs were normal in zDC/ mice compared 
with littermate controls (Fig. 2, D and E). However, the number 
of CD11c+MHCIIhi migratory DCs (mDCs), which arrive from 
can present antigen to MHC I– or MHC II–restricted T cells, 
CD4+/CD11b+ cDCs are better suited for antigen presenta-
tion on MHC II to induce CD4+ T cell responses, and CD8+/
CD103+ cDCs are specialized for cross-presentation on MHC I 
for CD8+ T cell responses (Dudziak et al., 2007; Kamphorst 
et al., 2010; Hashimoto et al., 2011).
zDC is an evolutionarily conserved broad complex, tram-
track, bric-a-brac and zinc finger protein (BTB-ZF) transcrip-
tion factor which is specifically expressed by cDCs in humans 
and mice (Meredith et al., 2012; Satpathy et al., 2012). To 
understand the role of zDC in cDC development and 
homeostasis, we identified zDC’s target genes by ChIP-seq 
and produced zDC-deficient mice. We show that zDC associ-
ates with >1,000 gene promoters and acts as a transcriptional 
repressor of many of these target genes. Furthermore, cDC 
gene expression is profoundly altered in the absence of zDC, 
resulting in aberrant partial induction of activation and matu-
ration pathways in the steady state.
RESULTS
zDC target genes
zDC is a member of the BTB-ZF transcription factor family 
and is therefore likely to function as a transcription factor. To 
identify genes regulated by zDC, we performed chromatin 
immunoprecipitation sequencing (ChIP-seq) on steady-state 
splenic cDCs. Genome-wide, zDC was enriched in a region 
100 base pairs upstream of transcription start sites (TSSs), 
which would optimally position it to interact with transcrip-
tional machinery (Fig. 1 A). For example, zDC binds upstream 
of the first exon of all four classical MHC II genes expressed 
by C57BL/6 mice (Fig. 1 B). Furthermore, zDC can also 
associate with elements downstream of the final exon (Fig. 1 B), 
suggesting that it may bind to enhancers and other regulatory 
elements outside of promoters.
zDC contains two C2H2 zinc finger domains, each of 
which should bind a unique trinucleotide sequence (Bulyk 
et al., 2001), and therefore zDC would be predicted to 
recognize a six-nucleotide sequence motif. To identify zDC’s 
DNA binding motif, we used MEME software to identify a 
consensus motif in the zDC ChIP-seq library (Bailey et al., 
2009). MEME software identified a 10-nucleotide sequence 
featuring a prominent 6-nucleotide TGACGT core motif 
(Fig. 1 C). To test the binding of zDC to this predicted 
sequence, we performed gel shift assays between recom-
binant zDC and double-stranded DNA probes contain-
ing the predicted binding motif or control probe with a 
scrambled version of the motif. We found that zDC bound 
to the probe containing the predicted 6-nucleotide motif but 
not the scrambled control (Fig. 1 D). Consistent with this 
finding, our ChIP-seq library identified 1,309 genes occu-
pied by zDC (Fig. 1 E), >99% of which contained the 
TGACGT consensus motif within 1 kilobase of the TSS 
(P < 0.01). zDC binding sites did not consistently co-
localize within 1 kilobase of other specific cis-regulatory 
elements defined in the Open Regulatory Annotation 
(ORegAnno) database.
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Figure 1. zDC target genes. (A) Genome-wide location of zDC-associated sequences relative to the closest gene’s TSS. The number of genes at various 
distances from the TSS is shown on the y axis. (B) zDC ChIP reads relative to MHC II genes. Histograms show zDC density, and boxes below each histo-
gram show the exon structure of the MHC genes at that position. A 1-kb scale bar is included for each locus. (C) Consensus motif for zDC ChIP sequences. 
(D) Gel shift assay with predicted zDC motif and mutant probe with scrambled motif. Two concentrations of zDC protein are included, as well as glutathione  
S-transferase (GST) control protein. The gel is representative of three independent experiments with comparable results. (E) Pie chart shows gene families 
represented among zDC ChIP target genes. Gene ontologies for target genes were determined by PANTHER Classification (pantherdb.org). Numbers in 
parentheses indicate the number of genes included in the indicated group. (F) Genome-wide distribution of zDC target genes. The mouse genome was 
divided into 10-Mbp segments and the number of zDC target genes within each segment is shown. Alternating red and black portions and matching 
numbers indicate chromosome number. (G) Fold difference expression of zDC target gene probes by cDCs relative to monocytes. Red bars indicate probes 
expressed at higher levels in cDCs, and blue for those in monocytes. Probes expressed equally by cDCs and monocytes (i.e., less than twofold difference) 
are not shown.
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mice showed approximately equal 
numbers of CD4+ and CD8+ cDCs 
(Fig. 2 F). zDC+/ mice likewise dem-
onstrated CD4+ cDC reduction and 
CD8+ cDC expansion, and subset com-
position in zDC+/ and zDC/ mice 
did not significantly differ (P = 0.830 
and 0.136 for CD4+ and CD8+ cDC 
numbers, respectively). CD4CD8 
double-negative cDCs were not sig-
nificantly affected by zDC deficiency. 
We conclude that zDC is not required for early cDC develop-
ment, but zDC deficiency alters the proportions of CD4+ and 
CD8+ cDCs in the spleen and results in a small increase of mDC 
numbers in the skin-draining LNs.
zDC regulation of gene expression
To determine the effects of zDC deficiency on cDC gene 
expression genome-wide, we compared gene array expression 
the skin via CCR7-dependent migration after maturation 
(Alvarez et al., 2008), were slightly increased in the skin-draining 
LNs of zDC+/ and zDC/ mice (Fig. 2 E). Furthermore, al-
though zDC/ mice contained the same number of total cDCs 
as wild-type littermates, zDC/ mice contained fewer splenic 
CD4+ cDCs and reciprocally greater numbers of CD8+ cDCs 
(Fig. 2 F). Whereas CD4+ cDCs were threefold more abundant 
than CD8+ cDCs in wild-type littermate controls, zDC-deficient 
Figure 2. zDC deficiency does not  
impair cDC development but skews sub-
set composition in the spleen and LNs.  
(A) Targeted allele compared with wild type. 
The BTB protein dimerization domain in 
exon 2 and two C2H2 zinc finger domains in 
exon 4 are labeled. Red triangles represent 
loxP sites. (B) Western blot for zDC and 
Histone H4 loading control in purified 
splenic cDCs from zDC+/+ and zDC/ mice. 
Black lines indicate that intervening lanes 
have been spliced out. (C) Percent abun-
dance of CD3B220NK1.1(Lin)Sca-1 
CD11bCD11cFlt3+CD115+ CD117hi mac-
rophage and DC progenitor (MDP), LinSca-1
CD11bCD11cFlt3+CD115+CD117lo  
common DC progenitor (CDP), and 
LinMHCIICD11c+Flt3+ pre-DC populations 
in bone marrow from wild-type (blue) and 
zDC/ (red) mice. Results are pooled from 
three experiments. (D) Flow cytometry plots 
of CD11chiMHCII+ cDCs from the spleens of 
zDC+/+, zDC+/, and zDC/ mice. Numbers 
indicate percentage of total spleen cells. The 
graph on the right summarizes results from 
four experiments. Horizontal bars show 
means. (E) As in D, but in skin-draining LNs 
(skLN). Numbers adjacent to CD11chiMHCII+ 
cDC (red) and CD11chiMHCII+ mDC gates 
(blue) indicate percentage of total skin-
draining LN cells. The graph on the right 
summarizes results from three experiments. 
(F) Flow cytometry plots gated on  
CD11chiMHCII+ splenic cDCs from zDC+/+, 
zDC+/, and zDC/ mice. Numbers adjacent 
to CD4 (green) and CD8 (orange) gates indi-
cate percentage of cDCs, and the graph on 
the right shows percent of total spleen cells. 
Results pooled from four experiments.
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self-derived activation signals. Signaling through these re-
ceptors induces cDC maturation, including the up-regulation 
of MHC II and co-stimulatory markers, which enables cDCs 
to stimulate adaptive immune responses (Steinman 2007). 
GSEA software showed that multiple activation and inflam-
matory pathways are up-regulated in zDC-deficient cDCs, 
including gene sets up-regulated in response to LPS (Foster 
et al., 2007) and by treatment with TNF/IL-1 (Lindstedt 
et al., 2002; Fig. 4 A; P < 0.005). Furthermore, in addition 
to the transcriptional up-regulation of these gene sets, 
zDC/ cDCs expressed up to twofold higher MHC II lev-
els by flow cytometry compared with wild-type littermates 
(Fig. 4 B). Therefore, steady-state zDC-deficient cDCs up-
regulate the expression of gene pathways that are normally 
only expressed after activation.
Because zDC-deficient steady-state cDCs appear to phe-
nocopy some aspects of cDC activation, we asked whether 
zDC expression is normally modulated during cDC activa-
tion by measuring zDC protein after TLR stimulation. As 
early as 3 h after poly I:C injection, zDC protein could not be 
detected in splenic cDCs by Western blotting (Fig. 4 C). In 
addition to poly I:C, other TLR agonists including LPS and 
CpG also rapidly down-regulated zDC protein (unpublished 
data). This loss of zDC protein expression is not the result 
of a loss of zDC transcription because zDC transcripts are 
still expressed by splenic cDCs 3 h after poly I:C injection 
(Fig. 4 D) as well as by lung cDCs in poly I:C–stimulated 
mice and gut cDCs in Salmonella-infected mice (immgen.
org). We conclude that zDC protein is down-regulated after 
TLR stimulation, most likely via posttranslational regulation. 
The down-regulation of zDC protein after TLR stimulation 
is consistent with the up-regulation of MHC II expression 
during cDC matu-
ration (Cella et al., 
1997; Landmann 
et al., 2001).
data from wild-type and zDC-deficient splenic CD8+ and 
CD4+ cDCs. Overall, 2,653 genes were up-regulated, whereas 
1,195 genes were down-regulated in CD4+ zDC/ cDCs 
(Fig. 3 A). Similarly, 2,333 genes were up-regulated and 1,078 
genes down-regulated in CD8+ zDC/ cDCs. These effects 
on gene expression in zDC/ cDCs were highly correlated 
between CD4+ and CD8+ cDCs (Fig. 3 B; m = 0.78 ± 0.0023; 
r2 = 0.73). To validate our microarray dataset, we compared 
the expression of a subset of genes in wild-type and zDC-
deficient cDCs by quantitative PCR (Q-PCR; Fig. 3 C). 
Therefore, zDC deficiency profoundly alters the transcriptional 
profiles of CD4+ and CD8+ cDCs, and these changes are 
shared in both subsets of cDCs.
To better appreciate the function of zDC at its target 
genes, we compared the expression of zDC-bound genes 
identified by ChIP-seq with gene set enrichment analysis 
(GSEA; Subramanian et al., 2005). Overall, zDC target 
genes were up-regulated in zDC-deficient cDCs (Fig. 3 D; 
P < 0.001). Furthermore, when we compared the expres-
sion of zDC target genes up-regulated in wild-type cDCs 
or wild-type monocytes (defined in Fig. 1 G) to those 
that differed between wild-type and zDC-deficient cDCs, 
monocyte-up-regulated target genes were uniformly up-
regulated by zDC-deficient cDCs (Fig. 3 E). Conversely, cDC-
up-regulated target genes were more randomly deregulated 
(Fig. 3 E). This up-regulation of zDC-bound genes in the 
knockout, particularly among those genes typically ex-
pressed higher by monocytes, is consistent with the idea 
that zDC acts as a transcriptional repressor at many of its 
targets, similar to other members of the BTB-ZF family 
(Collins et al., 2001; Kelly and Daniel 2006; Beaulieu and 
Sant’Angelo 2011).
zDC deficiency results in partial activation in the steady state
cDCs express numerous pathogen recognition molecules and 
signaling receptors which allow them to sense pathogen- and 
Figure 3. zDC deficiency alters cDC gene 
expression. (A) Relative log2 expression of all 
Affymetrix Mouse430-2 probes by wild-type 
CD4+ cDCs on the x axis compared with 
zDC/ CD4+ cDCs on the y axis. Each probe is 
represented by a single box. The bold red line 
represents equal expression, and probes lo-
cated outside secondary red lines are ex-
pressed at greater than twofold difference.  
(B) Ratio of expression between zDC/ and 
wild-type cDCs for all Affymetrix Mouse430-2 
probes. Each box represents one probe. The 
black line shows linear regression of all points 
(m = 0.78 ± 0.0023; r2 = 0.74). (C) Relative 
log2 expression by zDC/ and wild-type cDCs 
for the genes Stat3 (1459961_a_at), Creb1 
(1428755_at), and Phf7 (1420260_at) deter-
mined by microarray and Q-PCR. (D) GSEA 
plot comparing gene array expression of zDC 
target genes by zDC/ (left) and wild-type 
cDCs (right; P < 0.001). (E) Relative log2 ex-
pression of zDC target genes up-regulated in 
wild-type cDCs or monocytes (red and blue, 
respectively, as defined in Fig. 1 G) by zDC/ 
and wild-type cDCs. SEM is shown with error 
bars in C and E.
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mice received 1–2 × 106 CFSE-labeled OT-I T cells and 
were treated with 3 µg DEC-205 antibody expressed as a 
fusion protein with OVA antigen (DEC-OVA). 2 wk after 
DEC-OVA targeting, OT-I cells were examined by flow 
cytometry. Whereas wild-type littermates deleted the trans-
ferred OT-I T cells, zDC-deficient mice retained CFSEloCD62lo 
OT-I T cells that had divided and developed phenotypic 
The choice between the induction of tolerance or adaptive 
immune responses is in part determined by the activation 
state of cDCs (Steinman and Nussenzweig 2002). To examine 
the consequences of zDC deficiency during antigen presen-
tation to T cells, we tested zDC/ cDCs for the ability to 
induce OVA-specific OT-I T cell tolerance (Hawiger et al., 
2001; Dudziak et al., 2007). Specifically, wild-type and zDC/ 
Figure 4. zDC-deficient cDC gene expression. (A) GSEA plots for inflammatory response after LPS exposure (Foster et al., 2007) and DC maturation 
(Lindstedt et al., 2002) gene sets significantly up-regulated in zDC/ compared with wild-type cDCs (P < 0.001). (B) Histograms depicting surface MHC II 
expression by splenic CD11chiCD8+ and CD11chiCD4+ cDCs. Results are representative of four experiments. (C) Western blot for zDC expression by CD11c-
enriched splenic cDCs from naive wild-type mice, wild-type mice 3 h after i.v. injection with 30 µg poly I:C, and naive zDC/ mice. The histone H4 blot is 
included as a loading control. (D) zDC transcript expression by splenic CD4+ and CD8+ cDCs from naive wild-type mice and wild-type mice 3 h after i.v. 
injection with 30 µg poly I:C. zDC levels normalized to Gapdh. Each point represents a single mouse from three independent experiments. (E) Surviving 
CD8+CD45.1+V2+ OT-I T cells measured by flow cytometry in the spleens of wild-type and zDC/ mice 2 wk after treatment with 3 µg DEC-OVA. The 
graph on the right shows results from three experiments with each point representing a single mouse. Horizontal bars show means. (F) Histogram show-
ing CFSE labeling on CD8+CD45.1+V2+ OT-I T cells described in E. The gray shaded curve represents cells collected from PBS controls, the blue line from 
DEC-OVA–treated wild-type mice, and the red line from DEC-OVA–treated zDC/ mice. (G) CD62L expression on surviving OT-I cells described in E.  
The graph on right shows results pooled from three experiments with each point representing a single mouse.
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its expression in zDC/ cDCs. Gene array analysis suggested 
Vegfc is up-regulated in zDC/ CD4+ cDCs (Fig. 5 E), and 
this up-regulation was confirmed by Q-PCR (Fig. 5 F). Con-
sistent with elevated Vegfc mRNA, popliteal LNs collected 
from zDC/→zDC+/+ bone marrow chimeras contained more 
VEGF than control bone marrow chimeras (Fig. 5 G), dem-
onstrating that zDC-deficient hematopoietic cells contribute 
to elevated VEGF levels in LNs. However, Vegfc is not a zDC 
target by ChIP-seq. Therefore, elevated Vegfc expression by 
zDC-deficient cDCs is likely an indirect effect of cDC 
maturation. We conclude that zDC represses genes that control 
VEGF expression and that this inhibition is normally abrogated 
during inflammation upon TLR ligation.
DISCUSSION
zDC is a member of the BTB-ZF family. This family contains 
dozens of members, many of which control immune cell de-
velopment and function (Collins et al., 2001; Kelly and Daniel 
2006; Beaulieu and Sant’Angelo 2011). BTB-ZF transcription 
factors typically regulate gene expression by binding to specific 
DNA sequences via their DNA-binding zinc finger domains 
and recruiting cofactors that mediate chromatin remodeling 
features of effector cells (Fig. 4, E–G). Conversely, naive OT-I 
T cells from wild-type mice that did not receive DEC-OVA 
treatment, as well as the few remaining OT-I T cells from 
DEC-OVA–treated wild-type mice, maintained a naive phe-
notype indicated by high expression of CD62L (Fig. 4 G). 
Therefore, OVA presentation to OT-I cells by steady-
state zDC/ cDCs does not result in complete deletion 
of OT-I T cells.
Increased lymphangiogenesis in zDC/ mice
zDC-deficient mice have enlarged skin-draining LNs with 
prominent blood vessels, which bear proportional expansion 
of B and T lymphocytes and a small relative increase of mDCs 
(Fig. 2 E; and Fig. 5, A–D). The degree of LN enlargement 
in zDC-deficient mice is similar to the amount of cDC-
dependent LN hypertrophy that has been reported in re-
sponse to TLR stimulation (Herman et al., 1972; Webster 
et al., 2006). TLR-stimulated cDCs mediate LN enlargement 
and angiogenesis by producing vascular endothelial growth 
factor (VEGF; Webster et al., 2006; Tzeng et al., 2010; Wendland 
et al., 2011). To determine if enhanced VEGF production by 
zDC-deficient cDCs contributes to LN expansion, we measured 
Figure 5. Enlarged skin draining LNs 
and increased VEGF expression by CD4+ 
cDC in zDC/ mice. (A, left) Photograph 
of spleen, popliteal, inguinal, and axillary 
LNs from wild-type and zDC-deficient mice. 
The ruler below shows millimeter incre-
ments. (A, right) Axillary LNs from wild-type 
(top) and zDC-deficient (bottom) mice 
showing increased vasculature in zDC/ 
LNs. (B) Weights of spleens (spl), popliteal 
(popLN), inguinal (ingLN), and axillary (ax-
iLN) LNs from wild-type and zDC-deficient 
mice. (C) Total cell counts from pooled skin-
draining LNs (skLN) in wild-type and zDC-
deficient mice. (D) Percent composition of B 
and T lymphocytes in skin-draining LNs 
from wild-type and zDC/ mice deter-
mined by flow cytometry. Results are pooled 
from four experiments. SEM is shown with 
error bars. (E) Log2-scaled heat maps for 
three Vegfc gene array probes showing 
Vegfc expression by splenic CD4+ and CD8+ 
cDCs collected from zDC+/+ and zDC/ 
mice. (F) Q-PCR for Vegfc expression by 
splenic CD4+ cDCs normalized to Gapdh 
expression. (G) Western blot for VEGF pro-
tein from whole popliteal LN extracts col-
lected from zDC+/+→zDC+/+ (+/+) and 
zDC/→zDC+/+ (/) bone marrow chi-
meras. -Actin is included as a loading 
control. The graph on the right shows VEGF 
band quantification normalized to -actin 
band intensity with ImageJ software from 
three experiments. Horizontal bars in C, F, 
and G show means.
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cDCs. According to this model, zDC degradation during 
TLR stimulation would alleviate the competition for MHC 
binding, permitting Creb1 to freely associate with MHC 
promoters. This scenario is consistent with the kinetics of 
zDC protein down-regulation within 3 h of TLR stimulation 
and the short burst of MHC transcription that occurs during 
the first 3–4 h after cDC maturation (Cella et al., 1997; Landmann 
et al., 2001). Further work is required to test whether zDC 
and Creb1 compete for MHC promoters and whether this 
competition also occurs at other zDC target genes.
Steady-state cDCs are in part responsible for maintaining 
immune tolerance to self- and innocuous antigens by in-
structing self-reactive T cells to undergo deletion, anergy, 
or differentiation into regulatory T cells (Hawiger et al., 2001, 
2004; Kretschmer et al., 2005). In contrast, antigen presenta-
tion by steady-state zDC/ cDCs to OT I cells resulted in an 
intermediate phenotype wherein many of the responding 
cells survive and acquire an effector T cell phenotype (CD62Llo). 
However, this break in peripheral tolerance is insufficiently 
penetrant to produce autoimmunity because we have not 
noticed any autoimmune disease (weight loss, proteinuria, 
or glycosuria) in zDC/ mice aged for up to 4 mo. Similar 
effects were also found in a second independently produced 
zDC knockout strain lacking exons 2 and 3.
zDC-deficient mice develop hyperplastic skin-draining 
LNs. This effect is consistent with increased VEGF produc-
tion by zDC/ cDCs. This growth factor is normally pro-
duced by activated cDCs after TLR stimulation and is required 
for the vascularization and growth of LNs in response to 
inflammation (Webster et al., 2006; Tzeng et al., 2010; 
Wendland et al., 2011). Because Vegfc is not a direct target 
of zDC in our ChIP-seq library, the up-regulation of VEGF 
is likely a downstream effect of zDC deficiency, for example, 
the up-regulation of cDC maturation pathways.
zDC is haploinsufficient, as indicated by altered cDC sub-
set composition and elevated MHC II expression in zDC+/ 
heterozygotes. This observation may be relevant to human 
disease because human zDC expression is cDC-restricted and a 
genome-wide association study identified single nucleotide 
polymorphisms (SNPs) within the human zDC gene that are 
associated with pediatric-onset inflammatory bowel disease 
(IBD; Kugathasan et al., 2008). Further work is necessary to ad-
dress the effects of these SNPs on zDC function and to evaluate 
zDC’s role in IBD and other human inflammatory diseases.
In conclusion, we have defined the genes regulated by the 
zinc finger zDC and its DNA recognition element. zDC is 
a repressor of a transcriptional network that is extinguished 
upon immune stimulation by TLR ligands. This network is 
in part responsible for maintaining cDC quiescence in the 
steady state.
MATERIALS AND METHODS
Antibodies and other reagents. The following reagents were from BD or 
eBioscience: anti–CD16-CD32 (2.4G2), anti–I-A/I-E (M5/114.15.2), anti-
CD45R (RA3-6B2), anti-CD115 (AFS98), anti-Flt3 (A2F10), anti-CD3 
(145-2C11), anti-CD4 (L3T4), anti-CD8 (53–6.7), anti-CD19 (1D3), anti-
NK1.1 (PK136), anti-Ter119 (TER-119), anti–Sca-1 (D7), anti-CD11b 
and transcriptional silencing or activation (Kelly and Daniel 
2006; Beaulieu and Sant’Angelo 2011).
In the immune system, BTB-ZF transcription factors, 
including Bcl6, PLZF, ThPOK, PLZP, MARZ, BAZF, LRF, 
and Miz, function as transcriptional repressors that control 
lineage commitment decisions and cellular activation (Collins 
et al., 2001; Kelly and Daniel 2006; Beaulieu and Sant’Angelo 
2011). Bcl6 is a typical BTB-ZF transcriptional repressor that 
is required for germinal center B cell and follicular helper 
T cell development (Dent et al., 1997; Ye et al., 1997; Nurieva 
et al., 2009; Yu et al., 2009). Its effect on B cell differentiation 
is mediated in part through repression of Blimp-1, which 
is required for plasma cell development (Shaffer et al., 2000; 
Tunyaplin et al., 2004). Similarly, ThPOK is required for 
CD4+ T cell lineage commitment and iNKT function (He 
et al., 2005; Engel et al., 2010). ThPOK-deficient thymocytes 
bearing TCRs that would normally differentiate into CD4+  
T cells or iNKT cells are instead diverted toward CD8+ T cell 
commitment. This redirection is a result of the loss of ThPOK-
mediated repression of CD8+ T cell determinants, including 
Runx3 (Beaulieu and Sant’Angelo 2011). In contrast, PLZP 
primarily modulates T cell proliferation and cytokine secretion 
after TCR stimulation (Piazza et al., 2004). PLZP-deficient 
CD4+ T cells become hyperproliferative after TCR signaling 
and produce excessive IL-4, IL-5, and IL-13. Likewise, stimu-
lated PLZP-deficient CD8+ T cells also hyperproliferate and 
produce more IFN-. Less is known about what roles BTB-PZ 
transcription factors play in the development and regulation 
of myeloid lineage cells.
zDC is unique among members of the BTB-ZF family as 
it is highly restricted to cDCs (Meredith et al., 2012; Satpathy 
et al., 2012). Like other BTB-ZF factors, it acts primarily 
as a transcriptional repressor as evidenced by the up-regulation 
of zDC bound genes in zDC/ cDCs. zDC directly and/or 
indirectly represses the expression of genes normally induced 
during cDC maturation, including MHC II. GSEA analyses 
identified gene pathways associated with TLR signaling and 
immune stimulation are up-regulated in zDC-deficient cDCs. 
Consistent with the idea that the absence of zDC expres-
sion in zDC/ mice causes cDC activation, zDC protein 
levels rapidly decrease in response to TLR stimulation in 
wild-type cDCs. Thus, normal cDC maturation involves 
activation of positive regulators like NF-B (Rescigno et al., 
1998) but also the extinction of zDC, which actively helps 
maintain cDCs in the quiescent steady state.
Although zDC motifs are located in the X2 box of MHC 
promoters, this position is also occupied by the MHC activator 
Creb1, suggesting that these two regulators with opposite effects 
on gene expression might compete for MHC promoter bind-
ing (Krawczyk et al., 2008; Handunnetthi et al., 2010). More-
over, zDC/ cDCs express higher Creb1 transcript levels 
than wild-type controls (Fig. 3 C), and ChIP-seq demonstrated 
that zDC binds the Creb1 locus. Therefore, zDC may directly 
repress Creb1 expression by occupying its promoter, thus 
lowering Creb1 expression and allowing zDC to outcompete 
Creb1 for occupation of MHC II promoters in steady-state 
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background by setting up littermate crosses. C57BL/6 mice were pur-
chased from The Jackson Laboratory, and CD45.1+ OT-I were bred and 
maintained at The Rockefeller University. All mice were housed in The 
Rockefeller University Comparative Bioscience Center under specific 
pathogen-free conditions, and all experiments were performed in accordance 
with National Institutes of Health guidelines and approved by The Rockefeller 
University Animal Care and Use Committee.
Microarray. Total RNA extraction and hybridization on MOE-430 2.0 
arrays (Affymetrix) were performed at Memorial Sloan-Kettering Cancer 
Center (New York, NY). Microarray data were analyzed using GeneSpring 
10.0 software (Affymetrix). Triplicates of each population were collected and 
averaged in GeneSpring. Splenic cDCs were collected from wild-type (GEO 
accession: GSE6259; Dudziak et al., 2007) and zDC/ (GEO accession: 
GSE37995) mice. Monocytes (GEO accession: GSE37566; Meredith et al., 
2012) were collected from wild-type bone marrow.
zDC down-regulation with poly I:C and other TLR agonists. 30 µg 
poly I:C (Invitrogen), 50 µg LPS serotype 0111:B4 (Sigma-Aldrich), 
or 20 µg 1826 CpG plus 15% DOTAP (Roche) in PBS was injected i.v. 
in C57/BL6 mice. 6 h after injection, mice were euthanized and spleen 
DCs were enriched with CD11c beads (Miltenyi Biotec) for analysis by 
Western blotting.
OT-I deletion. OT-I T cells were isolated from CD45.1+ OT-I mice using 
CD8+ T cell negative selection (Miltenyi Biotec) and were labeled with 2 µM 
CFSE (Molecular Probes). Each mouse received 1–2 × 106 CFSE-labeled OT-I 
T cells i.v. and 3 µg DEC-OVA i.p. or footpad s.c. 12–18 h after OT-I transfer. 
2 wk after DEC-OVA treatment, the amount of CD8+CD45.1+V2+ OT-I cells 
in the spleen were quantified by flow cytometry.
Quantitative real-time PCR. Total RNA was isolated from 20,000–100,000 
FACS-sorted C57BL/6 and zDC/ cDCs with TRIzol (Invitrogen), from 
which cDNA libraries were reverse-transcribed using Superscript II (Invitrogen) 
and random primers. Mouse Vegfc cDNA (forward: 5-TGTGTCCAGC-
GTAGATGAGC-3; reverse: 5-TGGCATGCATTGAGTCTTTC-3) was 
normalized to Gapdh cDNA (forward: 5-TGAAGCAGGCATCTGAGGG-3; 
reverse: 5-CGAAGGTGGAAGAGTGGGAG-3). All quantitative PCR re-
actions were performed with Brilliant SYBR Green (Agilent Technologies) 
on an Mx3005P system.
Online supplemental material. Table S1 shows zDC target genes. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20121003/DC1.
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